Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'

Ann Rheum Dis. 2023 Sep;82(9):e212. doi: 10.1136/annrheumdis-2020-219270. Epub 2020 Nov 3.

Authors

Ryu Watanabe¹, Motomu Hashimoto², Akio Morinobu³

Affiliations

¹ Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan ryuwatanabe@kuhp.kyoto-u.ac.jp.
² Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan.
³ Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

PMID: 33144301
DOI: 10.1136/annrheumdis-2020-219270

No abstract available

Keywords: antirheumatic agents; arthritis; autoimmune diseases; rheumatoid.

Publication types

Letter
Comment

MeSH terms

Abatacept
Antibodies, Monoclonal, Humanized
Antirheumatic Agents* / adverse effects
Hepatitis B* / complications
Hepatitis B* / drug therapy
Humans
Piperidines
Pyrimidines
Pyrroles / therapeutic use
Treatment Outcome

Substances

Antirheumatic Agents
Abatacept
Pyrroles
tocilizumab
Antibodies, Monoclonal, Humanized
tofacitinib
Piperidines
Pyrimidines